Medical Oncology

, Volume 27, Issue 3, pp 919–925 | Cite as

Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy

  • Guang-hui Li
  • Dong-lin Wang
  • Yi-de Hu
  • Ping Pu
  • De-zhi Li
  • Wei-dong Wang
  • Bo Zhu
  • Ping Hao
  • Jun Wang
  • Xian-qiong Xu
  • Jiu-qing Wan
  • Yi-bing Zhou
  • Zheng-tang ChenEmail author
Original Paper


Radiation-induced acute intestinal symptoms (RIAISs) are the most relevant complication of abdominal or pelvic radiation. Considering the negative impact of RIAIS on patients’ daily activities, the preventive effects of berberine on RIAIS in patients were investigated. Thirty-six patients with seminoma or lymphomas were randomized to receive berberine oral (n = 18) or not (n = 18). Forty-two patients with cervical cancer were randomized to a trial group (n = 21) and control group (n = 21). Radiotherapy used a parallel opposed anterior and posterior. 300-mg berberine was administered orally three times daily in trial groups. Eight patients with RIAIS were treated with 300-mg berberine three times daily from the third to the fifth week. Toxicities, such as fatigue, anorexia/nausea, etc., were graded weekly according to CTC version 2.0. Patients with abdominal/pelvic radiation in the control group showed grade 1 fatigue, anorexia/nausea, colitis, vomiting, proctitis, weight loss, diarrhea and grade 2 anorexia/nausea, fatigue. Only grade 1 colitis, anorexia/nausea, and fatigue were seen in patients of abdominal radiation treated with berberine. Grade 1 fatigue, colitis, anorexia/nausea, and proctitis occurred in patients of pelvic radiotherapy treated with berberine. Pretreatment with berberine significantly decreased the incidence and severity of RIAIS in patients with abdominal/pelvic radiotherapy when compared with the patients of the control group (P < 0.05). RIAIS were reduced in patients with abdominal radiotherapy/pelvic radiation after receiving berberine treatment. Berberine significantly reduced the incidence and severity of RIAIS and postponed the occurrence of RIAIS in patients with abdominal or whole pelvic radiation.


Berberine Radiotherapy Acute intestinal symptoms 


  1. 1.
    Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.CrossRefPubMedGoogle Scholar
  2. 2.
    Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut. 2005;54:1051–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Hauer-Jensen M, Wang J, Denham JW. Bowel injury: current and evolving management strategies. Semin Radiat Oncol. 2003;13:357–71.PubMedGoogle Scholar
  4. 4.
    Denham JW, Hauer-Jensen M. The radiotherapeutic injury—a complex “wound”. Radiother Oncol. 2002;63:129–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Hwang JM, Chan DC, Chang TM, Tsao TY, Tsou SS, et al. Effects of oral arginine and glutamine on radiation-induced injury in the rat. J Surg Res. 2003;109:149–54.CrossRefPubMedGoogle Scholar
  6. 6.
    Türkoğlu ÜM, Erbil Y, Öztezcan S, Olgaç V, Toker G, et al. The effect of selenium and/or vitamin E treatments on radiation-induced intestinal injury in rats. Life Sci. 2000;66:1905–11.CrossRefGoogle Scholar
  7. 7.
    Savarese DMF, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29:501–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Jang CS. The action of berberine on mammalian hearts. J Pharmacol Exp Ther. 1941;1:178–86.Google Scholar
  9. 9.
    Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and vivo. Cancer Lett. 2004;203:127–37.CrossRefPubMedGoogle Scholar
  10. 10.
    Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss; 1997.Google Scholar
  11. 11.
    International Commission on Radiation Units and Measurements. ICRU report 50: prescribing, recording, and reporting photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993.Google Scholar
  12. 12.
    Sanguineti G, Franzone P, Marcenaro M, Foppiano F, Vitale V. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma: a randomized study. Strahlenther Onkol. 2003;179:464–70.PubMedGoogle Scholar
  13. 13.
    O’Brien PC, Franklin CI, Dear KB, Hamilton CC, Poulsen M, et al. A phase III doubleblind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol. 1997;45:117–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Kneebone A, Mameghan H, Bolin T, Berry M, Turner S, et al. The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: a double-blind, randomized trial. Int J Radiat Oncol Biol Phys. 2001;51:628–35.PubMedGoogle Scholar
  15. 15.
    Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18:2226–33.PubMedGoogle Scholar
  16. 16.
    Kouvaris J, Kouloulias V, Malas E, Antypas C, Kokakis J, et al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors: a phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol. 2003;179:167–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Kouloulias VE, Kouvaris JR, Pissakas G, Kokakis JD, Antypas C, et al. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol. 2004;180:557–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Hille A, Schmidberger H, Hermann RM, Christiansen H, Saile B, et al. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63:1488–93.CrossRefPubMedGoogle Scholar
  19. 19.
    O’Brien PC, Franklin CI, Poulsen MG, Joseph DJ, Spry NS, et al. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial—Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2002;54:442–9.PubMedGoogle Scholar
  20. 20.
    Berthrong M. Pathologic changes secondary to radiation. World J Surg. 1986;10:155–70.CrossRefPubMedGoogle Scholar
  21. 21.
    Brown M. What causes the radiation gastrointestinal syndrome? Int J Radiat Oncol Biol Phys. 2008;70:799–800.PubMedGoogle Scholar
  22. 22.
    Molla M, Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol. 2007;13:3043–6.PubMedGoogle Scholar
  23. 23.
    Lee DU, Kang YJ, Park MK, Lee YS, Seo HG, et al. Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-a, iNOS, and IL-12 production in LPS-stimulated macrophages. Life Sci. 2003;73:1401–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, et al. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res. 2007;56:193–201.CrossRefPubMedGoogle Scholar
  25. 25.
    Kang BY, Chung SW, Cho D, Kim TS. Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid. Biochem Pharmacol. 2002;63:1901–10.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim TS, Kang BY, Cho D, Kim SH. Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxolo-quinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response. Immunology. 2003;109:407–14.CrossRefPubMedGoogle Scholar
  27. 27.
    Yesilada E, Küpeli E. Berberis crataegina DC root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and rats. J Ethnopharmacol. 2002;79:237–48.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, et al. Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol. 2008;35:303–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Shirwaikar A, Shirwaikar A, Rajendran K, Punitha IS. In vitro antioxidant studies on the benzyl tetra isoquinoline alkaloid berberine. Biol Pharm Bull. 2006;29:1906–10.CrossRefPubMedGoogle Scholar
  30. 30.
    Li F, Wang HD, Lu DX, Wang YP, Qi RB, et al. Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice. Acta Pharmacol Sin. 2006;27:1199–205.CrossRefPubMedGoogle Scholar
  31. 31.
    Liu Y, Yu H, Zhang C, Cheng Y, Hu L, et al. Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur J Cancer. 2008;44:2425–32.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Guang-hui Li
    • 1
  • Dong-lin Wang
    • 2
  • Yi-de Hu
    • 1
  • Ping Pu
    • 1
  • De-zhi Li
    • 1
  • Wei-dong Wang
    • 1
  • Bo Zhu
    • 1
  • Ping Hao
    • 1
  • Jun Wang
    • 3
  • Xian-qiong Xu
    • 1
  • Jiu-qing Wan
    • 1
  • Yi-bing Zhou
    • 1
  • Zheng-tang Chen
    • 1
    Email author
  1. 1.Institute for Cancer Research in People’s Liberation ArmyXinqiao Hospital, Third Military Medical UniversityChongqingChina
  2. 2.Department of OncologySichuan Provincial People’s HospitalChengduChina
  3. 3.Department of OncologyJinan Military Region General HospitalJinanChina

Personalised recommendations